JPS6360908A - Skin drug for external use - Google Patents
Skin drug for external useInfo
- Publication number
- JPS6360908A JPS6360908A JP61205634A JP20563486A JPS6360908A JP S6360908 A JPS6360908 A JP S6360908A JP 61205634 A JP61205634 A JP 61205634A JP 20563486 A JP20563486 A JP 20563486A JP S6360908 A JPS6360908 A JP S6360908A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- blended
- drug
- keratinous
- external use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940079593 drug Drugs 0.000 title abstract description 11
- 239000003814 drug Substances 0.000 title abstract description 11
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000003242 anti bacterial agent Substances 0.000 claims description 11
- 102000011782 Keratins Human genes 0.000 claims description 3
- 108010076876 Keratins Proteins 0.000 claims description 3
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 14
- 206010000496 acne Diseases 0.000 abstract description 14
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 abstract description 12
- 229960001755 resorcinol Drugs 0.000 abstract description 11
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract description 8
- 239000011593 sulfur Substances 0.000 abstract description 8
- 229910052717 sulfur Inorganic materials 0.000 abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 abstract description 6
- -1 e.g. Chemical compound 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 6
- 239000002674 ointment Substances 0.000 abstract description 6
- 230000001256 tonic effect Effects 0.000 abstract description 6
- 229930007845 β-thujaplicin Natural products 0.000 abstract description 6
- 239000006071 cream Substances 0.000 abstract description 5
- 239000006210 lotion Substances 0.000 abstract description 5
- 208000001840 Dandruff Diseases 0.000 abstract description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract description 4
- 229960004889 salicylic acid Drugs 0.000 abstract description 4
- 210000004761 scalp Anatomy 0.000 abstract description 4
- SLYPOVJCSQHITR-UHFFFAOYSA-N tioxolone Chemical compound OC1=CC=C2SC(=O)OC2=C1 SLYPOVJCSQHITR-UHFFFAOYSA-N 0.000 abstract description 4
- 229960003070 tioxolone Drugs 0.000 abstract description 4
- 230000003054 hormonal effect Effects 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 241000207901 Cuscuta Species 0.000 abstract 4
- 239000004599 antimicrobial Substances 0.000 abstract 3
- 239000002671 adjuvant Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 15
- 208000002874 Acne Vulgaris Diseases 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野] 、本発明
は皮膚外用剤に関する。 更に詳しくは、本発明は、生
薬であるトシシまたはその抽出エキスとたとえばイオウ
、ヒノキチオール、感光素201号およびチオキソロン
等の抗菌剤および/またはサリチル酸、レゾルシン等の
角質剥離剤とを配合することを特徴とする皮膚外用剤に
関するもので、特にニキビの予防、治療、処置に有効に
働き、また、頭皮に使用してフケを有効に予防すること
ができる。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to an external skin preparation. More specifically, the present invention is characterized by blending the herbal drug Toshishi or its extract with antibacterial agents such as sulfur, hinokitiol, photosensor No. 201, and thioxolone, and/or exfoliating agents such as salicylic acid and resorcinol. The present invention relates to a skin preparation for external use, which is particularly effective in the prevention, treatment, and treatment of acne, and can also be used on the scalp to effectively prevent dandruff.
[従来の技術]
ニキビは主として思春期に発現する皮膚疾患で病名を尋
常性座麿といい、臨床的には”°毛嚢脂腺系を中心に毛
孔におこる慢性の炎症性変化°°と定義されている。
□
ニキビの病因は現在まだ明らかではなく、種々の要因が
複雑にからみあっている皮膚疾患ではあるが一般には、
皮脂分泌過剰、毛嚢角化、毛嚢内細菌が重要な役割を果
たしていると考えられている。[Prior art] Acne is a skin disease that mainly occurs during adolescence and is called zamaro vulgaris.Clinically, it is characterized by chronic inflammatory changes that occur in the pores, mainly in the pilosebaceous system. Defined.
□ The etiology of acne is still unclear, and although it is a skin disease in which various factors are intricately intertwined, in general,
Excessive sebum secretion, hair follicle keratinization, and bacteria within the hair follicle are thought to play important roles.
従って、ニキビ治療の外用剤としては、各要因に対応し
て皮脂分泌抑制剤および抗菌剤を配合したクリーム、軟
膏が一般に多用されている。しかし、既存の各種薬剤を
配合したニキビ治療剤には種々の欠点があった。たとえ
ば、皮脂分泌抑制剤であるエチニルエストラジオールは
表皮の生長を抑制し、脂腺の分泌を減少きせるものであ
るが、ホルモン剤がひきおこす副作用は思春期の男女に
とって好ましいものではない。また、たとえばイオウ、
ヒノキチオール、感光素201号およびレゾルシン等の
抗菌剤は、皮膚常在のニキビ菌であるプロピオニバクテ
リウムアクネスに対して、試験管内で(r極めて高い抗
菌力を発揮しても、実際にクリーム、軟膏に配合してニ
キビ治療に用いると期待した治療効果を発揮しないのが
ほとんどである。Therefore, creams and ointments containing sebum secretion inhibitors and antibacterial agents are commonly used as external preparations for treating acne. However, existing acne treatment agents containing various drugs have various drawbacks. For example, ethinyl estradiol, a sebum secretion inhibitor, inhibits epidermal growth and reduces sebaceous gland secretion, but the side effects caused by hormones are not desirable for adolescents. Also, for example, sulfur,
Antibacterial agents such as hinokitiol, Photosensor No. 201, and resorcinol have shown to be extremely effective against Propionibacterium acnes, a bacteria resident on the skin, in vitro (r); When combined into ointments and used to treat acne, most of the time they do not exhibit the expected therapeutic effect.
[発明が解決しようとする問題点]
本発明者らは、従来の抗菌剤あるいは角質剥離剤の効果
を皮膚上で増大させ、特にニキビの予防、治療、処置に
有効に働き、また、頭皮に使用してフケを有効に予防す
ることができるような化合物を研究していたところ、生
薬であるトシシまたはその抽出物と、たとえばイオウ、
ヒノキチオール、感光素201号およびベルベリン等の
抗菌剤あるいはサリチル酸、レゾルシン等の角質剥離剤
とを配合することを特徴とする皮膚外用剤が、この目的
を達成できることを見いだして、本発明を完成した。[Problems to be Solved by the Invention] The present inventors have proposed that the effects of conventional antibacterial agents or exfoliating agents be increased on the skin, and that they are particularly effective in preventing, treating, and treating acne. While researching compounds that can be used to effectively prevent dandruff, we discovered that the herbal medicine Toshishi or its extract and, for example, sulfur,
The present invention was completed based on the discovery that an external skin preparation characterized by containing hinokitiol, Photosensor No. 201, and an antibacterial agent such as berberine, or a keratin exfoliant such as salicylic acid or resorcinol can achieve this objective.
[問題点を解決するための手段]
すなわち本発明はトシシまたはその抽出物と、抗菌剤お
よび/または角質剥離剤とを配合することを特徴とする
皮膚外用剤である。かかる皮膚外用剤は特にニキビの予
防、治療、処置に有効に働き、また、頭皮に使用してフ
ケを有効に予防することができる
以下本発明の構成について詳述する。[Means for Solving the Problems] That is, the present invention is a skin preparation for external use, which is characterized in that it contains Toshishi or an extract thereof, and an antibacterial agent and/or a keratin exfoliant. Such external skin preparations are particularly effective in preventing, treating, and treating acne, and can also be used on the scalp to effectively prevent dandruff.The structure of the present invention will be described in detail below.
本発明に用いられるトシシはネナシカズラの種子でもっ
ばら、強精、強壮薬として単味で、あるいは漢方製剤、
生薬製剤の一成分として用いられており、しかもそのほ
とんどが、内服薬であり、外用剤で用いられた例は少な
い。The toshishi used in the present invention is mainly the seeds of Kassula japonica, used alone as a tonic or tonic, or as a Chinese herbal preparation.
It is used as a component of crude drug preparations, and most of them are taken internally, and there are only a few examples of its use in external preparations.
本発明においてはトシシ末または水もしくは水性アルコ
ール、たとえばエタノールを用い、通常15〜25℃で
抽出処理して得られる。配合量は末、エキス(抽出溶媒
を留去した残分)ともに全組成中におおむね0.005
%(重量%)以上配合する。配合量の上限は特に限定す
るものではないが、着色等の商品価値の観点から乾燥残
分として合計で約10%まで配合するのが好ましい。In the present invention, it is obtained by extraction using toshishi powder or water or aqueous alcohol, such as ethanol, usually at 15 to 25°C. The blending amount is approximately 0.005% of the total composition, including the extract (residue after distilling off the extraction solvent).
% (weight %) or more. The upper limit of the amount to be blended is not particularly limited, but from the viewpoint of commercial value such as coloring, it is preferable to blend up to about 10% in total as a dry residue.
一方、本発明において配合可能な抗菌剤は具体的には以
下のようなものをざす。On the other hand, specific antibacterial agents that can be incorporated in the present invention are as follows.
イオウ・ヒノキチオール・トリクロサン・トリクロロカ
ルバニリド・クロルヘキシジン塩酸塩・クロルヘキシジ
ンクルコンサン塩・ハロカルパン・クロロフエネシン・
塩化ベンゼトニウム・塩化ベンザルコニウム・塩化リゾ
チーム・塩′酸アルキルジアミノエチルグリシン・イソ
プロピルメチルフェノール・安息香酸・感光素201号
・チモール・ヘキサクロロフェン・ベルベリン・レゾル
シンφチオキソロンおよびそれらの誘導体。Sulfur, hinokitiol, triclosan, trichlorocarbanilide, chlorhexidine hydrochloride, chlorhexidine cluconsanate, halocarpan, chlorophenesin,
Benzethonium chloride, benzalkonium chloride, lysozyme chloride, alkyldiaminoethylglycine chloride, isopropylmethylphenol, benzoic acid, photosensitizer No. 201, thymol, hexachlorophene, berberine, resorcin φ thioxolone and their derivatives.
配合量としては0.001%以上10%以下で、好まし
くは0.01%以上5%以下である。The blending amount is 0.001% or more and 10% or less, preferably 0.01% or more and 5% or less.
また本発明において使用可能な角質剥離剤としては具体
的に以下のようなものをきす。Further, as the exfoliating agent that can be used in the present invention, specifically, the following exfoliants are used.
イオウ・サリチル酸・レゾルシン・チオキソロン・ジベ
ンゾチオフェンおよびそれらの誘導体。Sulfur, salicylic acid, resorcinol, thioxolone, dibenzothiophene and their derivatives.
本発明においてはこれらの抗菌剤および角質剥離剤から
なる群から選ばれた任意の1種または2種以上か用いら
れる。In the present invention, any one or more selected from the group consisting of these antibacterial agents and exfoliating agents may be used.
配合量としてはおよそ0.01%以上20%以下である
。The blending amount is approximately 0.01% or more and 20% or less.
本発明の皮膚外用剤には、トシシまたはその抽出物と、
抗菌剤あるいは角質剥離剤のほかに、亜鉛およびその化
合物、乳酸等の薬剤や、および剤形によっても異なるが
、油分、界面活性剤、水、エタノール、保湿剤、増粘剤
、香料、色素等を本発明の効果を損なわない範囲で適宜
配合することができる。The skin external preparation of the present invention includes toshishi or an extract thereof;
In addition to antibacterial agents or exfoliants, zinc and its compounds, agents such as lactic acid, and depending on the dosage form, oils, surfactants, water, ethanol, humectants, thickeners, fragrances, pigments, etc. can be appropriately blended within a range that does not impair the effects of the present invention.
本発明の皮膚外用剤の剤形は、クリーム、軟膏、ローシ
ョン、トニック等外皮に適用できる性状のものであれば
いずれでも良い。The external preparation for skin of the present invention may be in any form as long as it can be applied to the skin, such as cream, ointment, lotion, or tonic.
[発明の効果]
トシシまたはその抽出物と、抗菌剤あるいは角質剥離剤
を配合する皮膚外用剤は非常に良く皮膚に浸透し、刺激
やホルモン様副作用を全く与えず、特にニキビの予防、
治療、処置に有効に働き、また、頭皮に使用してツウ゛
を有効に予防することができる。 [実施例]
実施例1 化粧水
ソルビトール(70%) 3.0gグリセリ
ン 5.○gレゾルシン
0.02g水
TO,ogこれらの成分を混合溶
解し、これに、
アラントイン 0.18gトシシエ
キス 1.0gポリオキシエチレ
ン硬化ヒマシ油誘導体0.5g
エタノール 20.3g香料
適量の混合溶液を攪拌しな
がら加えて均一な溶液として化粧水を得る。[Effects of the invention] A skin preparation for external use containing toshishi or its extract and an antibacterial agent or exfoliating agent penetrates the skin very well, does not cause any irritation or hormonal side effects, and is particularly effective in preventing acne.
It works effectively for treatment and treatment, and can also be used on the scalp to effectively prevent acne. [Example] Example 1 Lotion Sorbitol (70%) 3.0g Glycerin 5. ○g resorcinol
0.02g water
TO,og Mix and dissolve these ingredients, add allantoin 0.18g Toshishi extract 1.0g polyoxyethylene hydrogenated castor oil derivative 0.5g ethanol 20.3g fragrance
Add an appropriate amount of the mixed solution while stirring to obtain a lotion as a homogeneous solution.
実施例2 クリーム
ミツロウ 10.0gパラフィ
ンワックス 6.0gラノリン
3.0gイソプロピルミリステート
6.0gスクワラン
8.0g流動パラフィン 26.0g
トシシェキス 0.1gイオウ
2.Og塩化リゾチーム
1.0gポリオキシエチレンソルビ
タン干ソノステアレート 2.
0gソルビタンモノステアレート 4.2g防腐
剤 適量この成分を混合し
、約75℃で加熱し溶解し、これに約75℃で、加熱し
た、
プロピレングリコール 2.○gホウ砂
0.7g水
29.0gの混合液を攪
拌しながら加え、冷却し、55℃で香料を適量加え、4
5℃まで攪拌をつづけ、放置してクリームを得る。Example 2 Cream beeswax 10.0g paraffin wax 6.0g lanolin
3.0g isopropyl myristate
6.0g squalane
8.0g liquid paraffin 26.0g
Toshishekis 0.1g sulfur
2. Og lysozyme chloride
1.0g polyoxyethylene sorbitan dried sonostearate 2.
0g sorbitan monostearate 4.2g preservative Appropriate amount Mix these ingredients, heat at about 75°C to dissolve, and then heat to about 75°C Propylene glycol 2. ○g Borax
0.7g water
Add 29.0g of the mixture while stirring, cool, add an appropriate amount of fragrance at 55°C,
Continue stirring until 5°C and leave to obtain cream.
実施例3 ヘアトニック
エタノール 55.0gヒノキチ
オール 0.5gニッコールHCO
−60 1.0g香料
適量を室温下、溶解してアルコール用をff
な。Example 3 Hair tonic ethanol 55.0g Hinokitiol 0.5g Nikkor HCO
-60 1.0g fragrance
Dissolve an appropriate amount at room temperature and prepare for alcohol use.
Na.
トシシエキス 0.5g精製水
42・0gグリセリン
1.0g色素
適量の混合液を加熱下に溶解し冷Jし水相を得た
。Toshishi extract 0.5g purified water
42.0g glycerin
1.0g dye
An appropriate amount of the mixture was dissolved under heating and cooled to obtain an aqueous phase.
水相に前記アルコールf目を加え可溶化してヘアトニッ
クを得た。The alcohol f was added to the aqueous phase and solubilized to obtain a hair tonic.
実施例4 軟膏
固体パラフィン 10.ogピースワ
ックス 10.0gスクワラン
10.0gトシシエキス
1.0gイオウ
2.0g香料 適量ワセリ
ン 67.0g上記成分を混合
し、混合物を80℃に加熱溶解した後、攪拌冷却を行い
、軟膏を得た。Example 4 Ointment solid paraffin 10. og peace wax 10.0g squalane
10.0g Toshishi extract
1.0g sulfur
2.0g fragrance Appropriate amount Vaseline 67.0g The above ingredients were mixed, and the mixture was heated and dissolved at 80°C, and then cooled with stirring to obtain an ointment.
ざらに臨床例を挙げて本発明の効果を詳しく説明する。The effects of the present invention will be explained in detail by briefly giving clinical examples.
(使用薬剤)
下記処方、製造法で得たローションタイプの皮膚外用剤
を使用した。(Medicine used) A lotion-type skin external preparation obtained by the following formulation and manufacturing method was used.
トシシ抽出エキス 2.0gP、O,
E、(60モル)硬化ヒマシ油 2.0gグリセリ
ン 10.0gジプロピレングリコ
ール 10.Ogl、3−ブチレングリコール
5.0gポリエチレングリコール1500 5
.08以上を60’ Cで加熱溶解する。これにレゾル
シン 1.0gセチルイソオク
タネート 10.0gスクワラン
5.0gメチルパラベン
1.0gを同じ<60’Cに加熱溶解したものを添
加混合し、ホモミキサーで処理をしてゲルを作る。Toshishi extract 2.0gP, O,
E, (60 moles) hydrogenated castor oil 2.0 g glycerin 10.0 g dipropylene glycol 10. Ogl, 3-butylene glycol 5.0g polyethylene glycol 1500 5
.. 08 and above are heated and melted at 60'C. Add to this 1.0g of resorcinol and 10.0g of squalane.
5.0g methylparaben
Add and mix 1.0g of the solution heated to <60'C, and process with a homomixer to form a gel.
次にこのゲルに
カルボキシビニルポリマー 0.25gへキサメ
タリン酸ソーダ 0.03gを、イオン交換水
10.ogに溶解せしめたものを徐
添加しホモミキサーで分散した後、
水酸化カリウム 0.12gをイオン
交換水 38.6gに溶解したものを
添加混合し、ホモミキサーで乳化してローションタイプ
の皮膚外用剤を得た。Next, add 0.25 g of carboxyvinyl polymer and 0.03 g of sodium hexametaphosphate to this gel, and add ion-exchanged water.
10. Gradually add the solution dissolved in OG and disperse with a homomixer, then add and mix 0.12g of potassium hydroxide dissolved in 38.6g of ion-exchanged water, emulsify with a homomixer, and make a lotion type for external use on the skin. obtained the drug.
なお対照薬剤としてトシシ抽出エキスのみまたはレゾル
シンのみを配合した外用剤を用いた。In addition, as a control drug, an external preparation containing only Toshishiki extract or only resorcinol was used.
症例No、1〜10 レゾルシンのみ配合症例No、
11〜20トシシ抽出エキスのみ配合症例No、21〜
30 レゾルシン+トシシ抽出エキス配合
以上男女計30名に約1カ月使用させな。Case No. 1 to 10 Case No. containing only resorcinol,
11-20 Case No. 21-20 Contains only toshishi extract
30 Contains resorcinol + Toshishishi extract.A total of 30 men and women should use this product for about 1 month.
(使用方法)
化粧石鹸を用いて顔面をよく洗浄した後、支庁の上にの
み、前記したローションタイプの皮膚外用剤を1日に1
〜3回塗布せしめた。(How to use) After thoroughly washing your face with cosmetic soap, apply the above-mentioned lotion-type skin preparation once a day only on the branch area.
It was applied ~3 times.
(112察項目および観察日)
面昭、丘疹、膿庖の3症状について観察し、その個々の
所見の程度を総合して尋常性座癒の重篤度を、重症、中
等症、軽症の3段階に分けた。経過観察は、治療前、治
91週間後、2週間後、3週間後、4週間後の各回に行
った。(112 observation items and observation dates) The three symptoms of acne, papules, and pustules were observed, and the severity of acne vulgaris was determined by combining the severity of each individual finding: severe, moderate, and mild. Divided into stages. Follow-up observations were made before treatment, 91 weeks after treatment, 2 weeks after treatment, 3 weeks after treatment, and 4 weeks after treatment.
(全般改善度)
使用前に比較して使用薬剤による症状の改善度、著しく
軽快(++))、かなり軽快(什)、やや軽快(+)、
不変(±)、増悪(−)の5段階に分けた。(Overall improvement level) The degree of improvement in symptoms due to the drug used compared to before use: markedly relieved (++), considerably relieved (y), somewhat relieved (+),
It was divided into 5 stages: no change (±) and worsening (-).
(有用性)
全般改善度から、きわめて有用(1+))、かなり有用
(種)、やや有用(+)、無効(±)と判定した。(Usefulness) Based on the overall degree of improvement, it was judged as extremely useful (1+), quite useful (sort of), somewhat useful (+), and ineffective (±).
(以下余白)
(結果)
男7名、女23名計30名の臨床テスト結果は、感光素
201号のみ配合外用剤使用10名中十(やや有用)が
3名(30%)、±(無効)が7名(70$)、トシシ
抽出物のみ配合外用剤使用10名中+(やや有用)が3
名(30%)、±(無効)が7名(70%)、感光素2
01号十トシシ抽出物配合外用剤使用10名中’n+(
きわめて有用)が3名(30%)、什(かなり有用)が
4名(40り、+ (やや有用)が3名(30りであり
、本発明のニキビ治療効果が立証された。(Leaving space below) (Results) The clinical test results of a total of 30 people (7 men and 23 women) showed that out of 10 people who used only the external preparation containing Photosensor No. 201, 3 (30%) said it was 10 (somewhat useful), ± ( 7 people (70$) said it was ineffective), and 3 out of 10 people who used topical preparations containing only toshishi extract said it was + (slightly useful).
(30%), ± (invalid) 7 (70%), photosensitive element 2
Of the 10 people who used external preparations containing No. 01 Toshishishi extract, 'n+(
3 people (30%) said it was extremely useful, 4 people said it was quite useful (40%), and 3 people (30%) said it was + (slightly useful), proving the effectiveness of the present invention in treating acne.
Claims (1)
剥離剤とを配合することを特徴とする皮膚外用剤。1. A skin preparation for external use, characterized in that it contains toshishi or an extract thereof, and an antibacterial agent and/or a keratin exfoliant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61205634A JPS6360908A (en) | 1986-09-01 | 1986-09-01 | Skin drug for external use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61205634A JPS6360908A (en) | 1986-09-01 | 1986-09-01 | Skin drug for external use |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS6360908A true JPS6360908A (en) | 1988-03-17 |
Family
ID=16510137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61205634A Pending JPS6360908A (en) | 1986-09-01 | 1986-09-01 | Skin drug for external use |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6360908A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010069643A (en) * | 2001-04-24 | 2001-07-25 | 정구서 | Vitarlo sigger |
-
1986
- 1986-09-01 JP JP61205634A patent/JPS6360908A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010069643A (en) * | 2001-04-24 | 2001-07-25 | 정구서 | Vitarlo sigger |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112587446A (en) | Composition for treating acne and preparation method and application thereof | |
JP3611128B2 (en) | Testosterone-5-α-reductase inhibitor | |
JPH0582362B2 (en) | ||
JP2878353B2 (en) | External preparation for skin | |
JPS6360910A (en) | Skin drug for external use | |
JPH11269034A (en) | Skin prepafation for external use for improving acne | |
JPS63179812A (en) | External preparation for skin | |
JPS6322510A (en) | External preparation for skin | |
WO2003061676A1 (en) | Compositions for and method of treatment for skin ailments | |
JP2640101B2 (en) | External preparation for skin | |
JPS6360909A (en) | Skin drug for external use | |
JPH04124138A (en) | External preparation for skin | |
JPH11269043A (en) | Cosmetic for scalp and hair | |
JPS6360908A (en) | Skin drug for external use | |
JPS6322506A (en) | External preparation for skin | |
KR20040056079A (en) | Cosmetic composition for preventing and therapeutic for a pimple | |
JPS6322507A (en) | External preparation for skin | |
KR100467031B1 (en) | Acne prevention and treatment composition | |
JPH0517202B2 (en) | ||
JPH10265365A (en) | External preparation for skin for pimple | |
JPS6360935A (en) | Sebum suppressive agent | |
JPH043363B2 (en) | ||
JPH1179937A (en) | Skin lotion for pimple treatment | |
JPH01290614A (en) | Sebum secretion promoter | |
JPS63104928A (en) | Sebum-suppressing agent |